Abstract
Missing in metastasis (MIM) gene encodes an actin binding protein that is expressed at low levels in a subset of malignant cell lines. MIM protein tagged by green fluorescent protein (GFP) colocalizes with cortactin, an Arp2/3 complex activator, and interacts directly with the SH3 domain of cortactin. Recombinant full-length MIM promotes markedly cortactin and Arp2/3 complex-mediated actin polymerization in an SH3 dependent manner. In contrast, MIM-CT, a short splicing variant of MIM, binds poorly to cortactin in vitro and is unable to enhance actin polymerization. Full-length MIM binds to G-actin with a similar affinity as N-WASP-VCA, a constitutively active form of N-WASP, and inhibits N-WASP-VCA-mediated actin polymerization as analysed in vitro. The significance of the association of MIM with cortactin and G-actin was evaluated in NIH3T3 cells expressing several MIM constructs. Overexpression of full-length wild-type MIM-GFP inhibited markedly the motility of NIH3T3 cells induced by PDGF and that of human vein umbilical endothelial cells induced by sphingosine 1 phosphate. However, an MIM mutant with deletion of the WH2 domain, which is responsible for G-actin binding, enhanced cell motility. The motility inhibition imposed by MIM was compromised in the cells overexpressing N-WASP. In contrast, deletion of an MIM proline-rich domain, which is required for an optimal binding to cortactin, substantiated the MIM-mediated inhibition of cell motility. These data imply that MIM regulates cell motility by modulating different Arp2/3 activators in a distinguished manner.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Borisy GG and Svitkina TM . (2000). Curr. Opin. Cell Biol., 12, 104–112.
Bubb MR, Lewis MS and Korn ED . (1991). J. Biol. Chem., 266, 3820–3826.
Cheng L, Du C, Murray D, Tong X, Zhang YA, Chen BP and Hawley RG . (1997). Gene Ther., 4, 1013–1022.
Egile C, Loisel TP, Laurent V, Li R, Pantaloni D, Sansonetti PJ and Carlier MF . (1999). J. Cell Biol., 146, 1319–1332.
Evangelista M, Zigmond S and Boone C . (2003). J. Cell Sci., 116, 2603–2611.
Kim K, Hou P, Gorski JL and Cooper JA . (2004). Biochemistry, 43, 2422–2427.
Kinley AW, Weed SA, Weaver AM, Karginov AV, Bissonette E, Cooper JA and Parsons JT . (2003). Curr. Biol., 13, 384–393.
Lee YG, Macoska JA, Korenchuk S and Pienta KJ . (2002). Neoplasia, 4, 291–294.
Liu J, Huang C and Zhan X . (1999). Oncogene, 18, 6700–6706.
Li Y, Tondravi M, Liu J, Smith E, Haudenschild CC, Kaczmarek M and Zhan X . (2001). Cancer Res., 61, 6906–6911.
Makrides SC . (1996). Microbiol. Rev., 60, 512–538.
Martinez-Quiles N, Rohatgi R, Anton IM, Medina M, Saville SP, Miki H, Yamaguchi H, Takenawa T, Hartwig JH, Geha RS and Ramesh N . (2001). Nat. Cell Biol., 3, 484–491.
Mattila PK, Salminen M, Yamashiro T and Lappalainen P . (2003). J. Biol. Chem., 278, 8452–8459.
Millard TH, Sharp SJ and Machesky LM . (2004). Biochem. J., 380, 1–17.
Mullins RD, Heuser JA and Pollard TD . (1998). Proc. Natl. Acad. Sci. USA, 95, 6181–6186.
Pollard TD, Blanchoin L and Mullins RD . (2000). Annu. Rev. Biophys. Biomol. Struct., 29, 545–576.
Pollard TD and Borisy GG . (2003). Cell, 112, 453–465.
Safer D, Elzinga M and Nachmias VT . (1991). J. Biol. Chem., 266, 4029–4032.
Schafer DA, Weed SA, Binns D, Karginov AV, Parsons JT and Cooper JA . (2002). Curr. Biol., 12, 1852–1857.
Uruno T, Liu J, Li Y, Smith N and Zhan X . (2003). J. Biol. Chem., 278, 26086–26093.
Uruno T, Liu J, Zhang P, Fan Y, Egile C, Li R, Mueller SC and Zhan X . (2001). Nat. Cell Biol., 3, 259–266.
Weaver AM, Karginov AV, Kinley AW, Weed SA, Li Y, Parsons JT and Cooper JA . (2001). Curr. Biol., 11, 370–374.
Weiss S, Konig B, Morikawa Y and Jones I . (1992). Gene, 121, 203–212.
Woodings JA, Sharp SJ and Machesky LM . (2003). Biochem. J., 371, 463–471.
Wu H and Parsons JT . (1993). J. Cell Biol., 120, 1417–1426.
Yamagishi A, Masuda M, Ohki T, Onishi H and Mochizuki N . (2004). J. Biol. Chem., 279, 14929–14936.
Zhan X, Hu X, Hampton B, Burgess WH, Friesel R and Maciag T . (1993). J. Biol. Chem., 268, 24427–24431.
Acknowledgements
We thank Dr Pekka Lappalainen for providing plasmids encoding murine MIM. We also thank Drs Jian-Jiang Hao and Takehito Uruno for the critical reading of the manuscript. This work was supported by NIH Grants R01 HL 52753-10, R01 CA-91984-02 (to XZ).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lin, J., Liu, J., Wang, Y. et al. Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein. Oncogene 24, 2059–2066 (2005). https://doi.org/10.1038/sj.onc.1208412
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208412
Keywords
This article is cited by
-
MTSS1 suppresses mammary tumor-initiating cells by enhancing RBCK1-mediated p65 ubiquitination
Nature Cancer (2020)
-
Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control
Scientific Reports (2019)
-
MiR-423-5p in brain metastasis: potential role in diagnostics and molecular biology
Cell Death & Disease (2018)
-
Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis
Oncogene (2017)
-
MIM regulates the trafficking of bone marrow cells via modulating surface expression of CXCR4
Leukemia (2016)